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Activated leukocyte cell adhesion molecule (ALCAM/
CD166), a member of the immunoglobulin superfamily
with five extracellular immunoglobulin-like domains,
facilitates heterophilic (ALCAM-CD6) and homophilic
(ALCAM-ALCAM) cell-cell interactions. While expressed
in a wide variety of tissues and cells, ALCAM is re-
stricted to subsets of cells usually involved in dynamic
growth and/or migration processes. A structure-func-
tion analysis, using two monoclonal anti-ALCAM anti-
bodies and a series of amino-terminally deleted ALCAM
constructs, revealed that homophilic cell adhesion de-
pended on ligand binding mediated by the membrane-
distal amino-terminal immunoglobulin domain and on
avidity controlled by ALCAM clustering at the cell sur-
face involving membrane-proximal immunoglobulin do-
mains. Co-expression of a transmembrane ALCAM dele-
tion mutant, which lacks the ligand binding domain,
and endogenous wild-type ALCAM inhibited homophilic
cell-cell interactions by interference with ALCAM avid-
ity, while homophilic, soluble ligand binding remained
unaltered. The extracellular structures of ALCAM thus
provide two structurally and functionally distinguish-
able modules, one involved in ligand binding and the
other in avidity. Functionality of both modules is re-
quired for stable homophilic ALCAM-ALCAM cell-cell
adhesion.
Adhesion molecules play an important role in development,
leukocyte function, and homeostasis in multicellular organ-
isms, which are mainly governed by inter- and intracellular
communication via cell-cell interactions. Alterations in cellular
adhesion and communication can contribute to uncontrolled
cell growth (1) and life-threatening syndromes like leukocyte
adhesion deficiency (2). Activation of adhesion molecules gen-
erally involves both modulation of affinity and avidity. The
affinity of adhesion molecules often reflects a specific confor-
mation of the extracellular ligand-binding domain. Avidity
modulation involves changes in the cell surface distribution of
adhesion molecules (e.g. lateral oligomerization), which leads
to clusters of molecules and thereby specifically increases the
number of available receptors at the site of cell-cell interaction.
Activated leukocyte cell adhesion molecule (ALCAM/MEMD/
CD166)1 is a type I transmembrane protein and a member of
the Ig superfamily. It has over 90% homology with the chicken
adhesion molecule BEN/SC1/DM-GRASP (3–5), and it has 30%
identity and 50% similarity with the human melanoma cell
adhesion molecule Mel-CAM/MUC18/CD146 (6). Furthermore,
ALCAM has 93% sequence identity with the candidate liver high
density lipoprotein receptor HB2 (7). ALCAM is involved in var-
ious physiological processes including hematopoiesis (8, 9), thy-
mus development (10), the immune response (11), neurite exten-
sion (12), neural cell migration (13), and osteogenesis (14).
ALCAM has a short cytoplasmic tail and its extracellular
part comprises five Ig domains: two amino-terminal variable
(V) type Ig domains followed by three constant (C) type Ig
domains (V1V2C1C2C3). ALCAM was first identified as a CD6
ligand (15), but it also mediates homophilic ALCAM-ALCAM
interactions. While the heterophilic ALCAM-CD6 interaction is
extensively studied and mapped (16–18), little is known about
the molecular basis for the homophilic ALCAM-ALCAM inter-
action as observed in human melanoma (19, 20) and hemato-
poiesis (8, 9).
Previously, we have shown that homophilic ALCAM-medi-
ated cell-cell adhesion is regulated through actin cytoskeleton-
dependent clustering of ALCAM molecules at the cell surface
and that this clustering is necessary to obtain stable adhesive
interactions (21). In analogy with other members of the immu-
noglobulin superfamily like NCAM (22) and Ng-CAM/L1-CAM
(23), it is likely that the formation of ALCAM cis-homo-oli-
gomers at the cell surface is essential for strong ligand binding
and homophilic interactions.
Here we describe a detailed molecular analysis of the ho-
mophilic ALCAM interaction and the construction of an amino-
terminally deleted ALCAM molecule that inhibited wild-type
ALCAM-mediated aggregation in a dose-dependent manner.
These combined data lead us to propose a model for homophilic
ALCAM-mediated cell adhesion.
MATERIALS AND METHODS
Cell Lines—The adherent human melanoma cell lines BLM and 530
(24) were grown as monolayers in Dulbecco’s modified Eagle’s medium
as described before (19). The erythroleukemia cell line K562 growing in
suspension and ALCAM-transfected K562 cells were cultured as de-
scribed previously (21). Regular tests confirmed that cell lines were free
of mycoplasma contamination.
Monoclonal Anti-ALCAM Antibodies—Anti-ALCAM antibody J4-81
(MA250020, IgG1) was purchased from Antigenix America Inc. (Fran-
klin Square, NY). Monoclonal anti-ALCAM antibody AZN-L50 (IgG2a)
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was generated by immunization of BALB/c mice with K562-ALCAM
cells. Four consecutive days before fusion, mice were boosted intrave-
nously. The spleen was isolated, and spleen cells were fused with SP2/0
cells using standard technology. Supernatants of growing hybridomas
were tested in a cell enzyme-linked immunosorbent assay using K562-
ALCAM cells and K562 cells as a positive and negative control, respec-
tively. Positive hybridomas were recloned several times to obtain true
monoclonal hybridomas. The hybridoma AZN-L50 was selected for its
strong and specific binding to ALCAM and its ability to inhibit the
homophilic ALCAM-ALCAM interaction.
Plate Adhesion Assay—ALCAM-Fc recombinant protein consisting of
the five extracellular domains of ALCAM fused to the human IgG1 Fc
domain was produced and purified as described earlier (21). Adhesion of
cells to immobilized ALCAM-Fc was tested as described before (21).
Briefly, flat bottom maxisorp 96 wells plates (NUNC, Roskilde, Den-
mark) were coated with 4 mg/ml goat anti-human-Fc-F(ab9)2 in TSM (20
mM Tris, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, pH 8.0) for 1 h. Plates
were blocked with 1% (w/v) bovine serum albumin in TSM and subse-
quently coated with 250 ng/ml ALCAM-Fc for 1 h. Cells (2 3 104
cells/well) were labeled with Calcein-AM (Molecular Probes, Inc., Eu-
gene, OR) and preincubated with monoclonal anti-ALCAM antibody
J4-81 (5 mg/ml) and/or AZN-L50 (10 mg/ml) for 5–10 min at room
temperature. Cells were allowed to adhere in triplicate wells of the
coated plates for 20 min (530 cells) or 45 min (KG1, K562-ALCAM) in
culture medium at the indicated temperatures. Nonadherent cells were
removed by washing the wells five times with TSM plus 0.5% bovine
serum albumin at 37 °C. Cells were lysed with lysis buffer (50 mM Tris,
0.1% SDS), and fluorescence was quantified in a cytofluorometer (Per-
Septive Biosystems). Adhesion was expressed as the percentage
(mean 6 S.D.) bound cells of the total cells allowed to adhere in tripli-
cate wells.
Soluble ALCAM-Fc Binding Assay—For soluble ALCAM-Fc binding,
the indicated concentrations of ALCAM-Fc were added to 5 3 104 cells
in culture medium in V-bottom wells in a final volume of 50 ml. After an
incubation of 30 min at 37 °C, cells were washed once with prewarmed
(37 °C) medium and subsequently incubated with a fluorescein isothio-
cyanate (FITC)-conjugated secondary goat anti-human Fc antibody
(Cappel Inc., West Chester, PA) in medium for 15 min at 37 °C. After
washing with prewarmed medium, cells were analyzed on a FACScan
(Becton Dickinson, Mountain View, CA). The mean fluorescence inten-
sity is a measure for the amount of ALCAM-Fc molecules bound to the
cells. The percentage of cells that have bound ligand was determined.
Construction of Amino-terminally Truncated ALCAM Mutants—
Amino-terminally truncated ALCAM mutants were generated using
the polymerase chain reaction and carefully chosen restriction sites in
pWD201 (2.1-kilobase pair ALCAM cDNA coding for the leader se-
quence, the two V-type and three C-type Ig domains, the transmem-
brane spanning domain, and the short cytoplasmic tail (V1V2C1C2C3) in
pZip-neo-(X)-1 containing the neomycin resistance gene (19)). A sche-
matic representation is shown in Fig. 1. The ALCAM leader sequence
was amplified using a 59 Rev/T3 primer (59-ATT ACG CCA AGC TCG
AA-39) and 39 primers extended with a suitable restriction site. For the
generation of pWD277 (V2C1C2C3-construct), the Rev/T3 and P9-PstI
(59-AG CAT GCC AGA AGG TAT GAT AAT GGT ATC TCC ATA T-39)
primer pair was used to amplify the leader sequence. The amplified
fragment was subsequently cloned in SstI/PstI-linearized pWD201. For
the generation of pWD275 (C1C2C3 construct), the leader was amplified
using the Rev/T3 and P8-BalI (59-CTG GCC AGA AGG TAT GAT AAT
GGT ATC TCC ATA T-39) primer pair and cloned in SstI/BalI-linearized
pWD201. Finally, pWD278 (C2C3 construct) was generated using the
Rev/T3 and P7-NheI (59-GCT AGC AGA TAT TGT GCA AGG TAT GAT
AAT GGT ATC TCC ATA T-39) primer pair. Thereafter, the fragment
was cloned in SstI/NheI-linearized pWD201. The sequences of all con-
structs were verified.
Transfection—FuGENE-6 transfection reagent (Roche Molecular
Biochemicals) was used to transfect the human melanoma cell lines
according to the manufacturer’s protocol. In brief, a mixture of Fu-
GENE-6 and circular DNA (3 ml and 0.5 mg, respectively) was added
dropwise to a 40% confluent monolayer in a six-well plate in medium.
After 48 h, medium was replaced with selection medium (medium plus
1 mg/ml G418 (Life Technologies, Inc.)). Neomycin-resistant colonies
were expanded and maintained in medium supplemented with 0.5
mg/ml G418.
Flow Cytometry: Cell Surface Expression and Aggregation Assay—
Cells (2 3 105) were incubated with the indicated mouse monoclonal
antibody at 4 mg/ml in PBA (phosphate-buffered saline containing 1%
bovine serum albumin and 0.05% NaN3) for 30 min at 4 °C, washed
three times with PBA, and further incubated with FITC-conjugated
goat anti-mouse IgG antibody (Dako, Glostrup, Denmark) for 30 min at
4 °C. After washing, positive cells were detected using a FACScan, and
the mean fluorescence intensity was determined.
The aggregation capacity of human melanoma cell lines was meas-
ured by a double colored assay as described previously (19). Briefly, two
separate cell suspensions were labeled fluorescent green or fluorescent
red with 5,6-sulfofluorescein diacetate (50 mg/ml in culture medium;
Molecular Probes) or hydroethidine (40 mg/ml in culture medium; Ply-
sciences, Warrington, PA), respectively. Following extensive washing,
cells were mixed in equal amounts and allowed to aggregate at 37 °C for
30 min. After incubation, cells were fixed by adding paraformaldehyde
to a final concentration of 0.5% (w/v) and subsequently analyzed using
a FACScan. Aggregation was expressed as the percentage of double
colored events of the total events.
Immunofluorescence—Immunofluorescence was performed on meth-
anol/acetone-fixed monolayers of cells grown on a glass surface as
described previously (19). Affinity-purified mouse monoclonal antibod-
ies were used at 4 mg/ml in phosphate-buffered saline.
Western Blotting—Cells (7 3 106) were lysed for 30 min on ice in 1 ml
of lysis buffer (25 mM Tris-HCl, pH 7.5, 1% Nonidet P-40, 100 mM KCl,
10 mM MgCl2, 0.25 mM dithioerythritol, 1 mM phenylmethylsulfonyl
fluoride, 1 mM benzamidine, 2 mM Na2VO4, 10 mg/ml leupeptin, 10
mg/ml aprotinin). Nuclei and the Nonidet P-40 insoluble fraction were
spun down at maximum speed in an Eppendorf centrifuge. Superna-
tants were stored at 280 °C.
Protein concentration was determined using the Bio-Rad protein
assay and reagents according to the supplier’s instructions. Equal
amounts of protein were subjected to 6.5% SDS-polyacrylamide gel
electrophoresis and subsequently transferred to Hybond-C pure mem-
brane (Amersham Pharmacia Biotech). Membranes were blocked for 1 h
at room temperature in Tris-buffered saline containing 0.05% Tween 20
(TBS-T) and 5% (w/v) low fat milk powder. After washing the mem-
branes three times with TBS-T, the blots were incubated with AZN-L50
(3 mg/ml in TBS-T supplemented with 3% (w/v) low fat milk powder) for
FIG. 1. Construction of NH2-terminally truncated ALCAM mu-
tants. Using the polymerase chain reaction and standard cloning pro-
cedures, deletion mutants of ALCAM were made as described under
“Materials and Methods.” Primers P9, P8, and P7 contained a PstI,
BalI, and NheI restriction site respectively, which facilitated cloning of
the generated fragment into double-digested ALCAM cDNA (pWD201)
at the SstI and the respective restriction enzyme site. V1 and V2, V-type
domains; C1, C2, and C3, C-type domains; TM, transmembrane domain;
cyto, cytoplasmic tail; P7, P8, and P9, primers 7–9; Rev/T3, reverse T3
primer.
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2 h at room temperature. Following three washes with TBS-T at room
temperature, the membranes were incubated with horseradish peroxi-
dase-conjugated rabbit anti-mouse IgG (1:2000, Dako, Glostrup, Den-
mark) in TBS-T plus 5% milk powder for 1 h at room temperature. After
three washes with TBS-T, proteins were visualized via the enhanced
chemiluminescent reaction (Amersham Pharmacia Biotech).
RESULTS
Monoclonal Anti-ALCAM Antibodies Have Differential Ef-
fects on ALCAM-mediated Cell Aggregation and Adhesion—To
elucidate the molecular mechanism underlying the homophilic
ALCAM-ALCAM interaction, the availability of function block-
ing monoclonal antibodies (mAbs) is virtually indispensable.
The ALCAM-antibody J4-81 has previously been described to
block heterophilic ALCAM-CD6 interactions (25). In contrast to
these findings, we observed that the addition of mAb J4-81
markedly increased homotypic cell clustering of ALCAM-posi-
tive but CD6-negative myelomonocytic KG1 cells (Fig. 2A).
Therefore, new mAbs were generated and selected for the ca-
pacity to specifically inhibit homophilic ALCAM-ALCAM inter-
actions. ALCAM mAb AZN-L50 completely inhibited the J4-81-
induced homotypic cell clustering of KG1 cells to background
levels (Fig. 2A). Ectopic expression of ALCAM in erythroleuke-
mic K562 cells (K562-ALCAM) resulted in the occurrence of
large ALCAM-mediated cell clusters in suspension that were
not observed in the parental K562 cells. While the addition of
mAb J4-81 could not further enhance cell clustering of K562-
ALCAM cells, mAb AZN-L50 completely blocked the spontane-
ous ALCAM-dependent cell clustering of these cells (Fig. 2A).
Neither mAb J4-81 nor AZN-L50 had any effect on ALCAM-
negative parental K562 cells (Fig. 2A).
Using human melanoma 530 cells, similar activating and
inhibiting effects of the monoclonal antibodies on ALCAM-
mediated aggregation were observed in an aggregation assay
analyzed by flow cytometry. While parental 530 cells do not
express ALCAM and do not aggregate, aggregation of these
cells is induced by ectopic expression of ALCAM (530/
V1V2C1C2C3) (19), and this clustering was further increased by
35% using mAb J4-81, whereas mAb AZN-L50 inhibited the
ALCAM-mediated aggregation by 25% as compared with the
untreated control (530/ALCAM) (Fig. 2B). Neither of the anti-
bodies had any effect on the ALCAM-negative vector control
530 cells that did not aggregate (Fig. 2B). A similar pattern of
FIG. 2. Monoclonal anti-ALCAM antibodies have differential effects on ALCAM-mediated cell aggregation and adhesion. A,
phase-contrast microscopy. Ectopic ALCAM expression in erythroleukemic K562 cells (K562-ALCAM) induced cell aggregation in culture, whereas
vector control K562 cells did not aggregate. mAb J4-81(5 mg/ml) could not further enhance this spontaneous aggregation, but the ALCAM-mediated
aggregation was efficiently inhibited by the mAb AZN-L50 (10 mg/ml). Both antibodies had no effect on vector control K562 cells. Aggregation of
wild-type ALCAM-expressing myelomonocytic KG1 cells significantly increased upon treatment with mAb J4-81. This J4-81-induced cell aggre-
gation was completely inhibited with mAb AZN-L50. B, cell-cell aggregation in the absence or presence of an anti-ALCAM mAb was quantified by
two-color flow cytometry. mAb J4-81 (5 mg/ml) increased the cell aggregation of the ectopically ALCAM-expressing human melanoma cell line
530/ALCAM with 35% as compared with the untreated cells, while mAb AZN-L50 (5 mg/ml) reduced this aggregation with 25% with respect to the
untreated control. Neither of the antibodies had any effect on the ALCAM-negative vector control cell line. Increasing concentrations of mAb
AZN-L50 up to 10 mg/ml did not further reduce the cellular aggregation (not shown). C, myelomonocytic KG1 cells were allowed to adhere to
immobilized recombinant human ALCAM-Fc, in the presence or absence of the ALCAM mAb J4-81 (5 mg/ml) or AZN-L50 (10 mg/ml) at the
indicated temperatures, and the percentage of adhering cells was determined. ALCAM-mediated cell adhesion was strongly induced by mAb J4-81.
This J4-81-induced adhesion was efficiently inhibited when tumor cells were incubated with mAb AZN-L50 (10 mg/ml) prior to adhesion.
mAb-induced adhesion required physiological temperature, since it was clearly inhibited at lower temperatures, indicating that J4-81 induction
of adhesion is not due to cross-linking of opposing ALCAM molecules.
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activation and blocking of adhesion by these mAbs was ob-
served when using the human melanoma cell line BLM ex-
pressing endogenous ALCAM (not shown).
In addition to cell-cell aggregation assays, we analyzed the
effect of mAbs J4-81 and AZN-L50 on ALCAM-mediated stable
cell adhesion to immobilized recombinant ALCAM-Fc. KG1
cells were allowed to adhere to an ALCAM-Fc-coated surface in
the presence or absence of ALCAM mAbs J4-81 and AZN-L50.
No ALCAM-mediated adhesion was observed in the absence of
mAbs. The addition of mAb J4-81 induced adhesion of KG1 to
immobilized ALCAM-Fc, which in turn was efficiently inhib-
ited by the addition of the function blocking mAb AZN-L50 at
physiological temperatures (Fig. 2C). To exclude the possibility
that mAb J4-81 enhanced cellular aggregation and adhesion
via cross-linking of two ALCAM molecules on opposing cells (or
immobilized ALCAM-Fc), adhesion of KG1 to immobilized
ALCAM-Fc was performed at lower, nonphysiological temper-
atures (Fig. 2C). The strong induction of ALCAM-mediated
adhesion of KG1 cells by mAb J4-81 was temperature-depend-
ent as the observed adhesion was reduced when cell adherence
was performed at room temperature or at 4 °C. Furthermore,
the adhesion of KG1 cells induced by mAb J4-81 is efficiently
blocked with mAb AZN-L50 (Fig. 2C). Similar results were
obtained with K562-ALCAM cells (not shown). Thus, a pair of
monoclonal antibodies was characterized that either activated
(J4-81) or blocked (AZN-L50) the homophilic ALCAM-ALCAM
interaction.
Domain Mapping of mAbs J4-81 and AZN-L50 to Specific Ig
Domains of ALCAM—The results of these functional studies
with mAbs are more informative when the respective antibody
epitopes are known. To identify the Ig domains that are in-
volved in the homophilic ALCAM-mediated interactions, do-
main mapping was performed for mAbs J4-81 and AZN-L50. A
series of progressively amino-terminally truncated ALCAM
mutants was generated and expressed in the ALCAM-negative
human melanoma cell line 530. The extracellular part of wild-
type ALCAM consists of two amino-terminal V-type domains
and three membrane-proximal C-type domains (i.e. V1V2C1-
C2C3). Immunofluorescence analysis was performed with the
anti-ALCAM antibodies on the transfected cells to identify the
domains required for antibody recognition (Table I). mAb J4-81
only recognized wild-type ALCAM, while mAb AZN-L50 recog-
nized all available ALCAM constructs. Thus, the epitope for
anti-ALCAM mAb J4-81 is mapped to domain V1, whereas that
for AZN-L50 is located in the C2C3 module of ALCAM.
The Amino-terminal Ig Domain V1 of ALCAM Is Required for
Ligand Binding and Homophilic Cell-Cell Interactions—The
adhesion, aggregation, and antibody mapping data obtained
from experiments using mAbs AZN-L50 and J4-81 (Fig. 2 and
Table I) suggest that the membrane-proximal domains C2C3
and the amino-terminal domain V1 are directly involved in
homophilic ALCAM-ALCAM interactions. To further explore
the role of domain V1 in ALCAM-mediated aggregation, the
series of amino-terminally truncated ALCAM mutants ex-
pressed in the ALCAM-negative human melanoma cell line 530
were subjected to flow cytometry to determine the cell surface
expression of the truncated ALCAM molecules, using mAb
AZN-L50 that recognizes the membrane-proximal domains
C2C3 of ALCAM (Fig. 3A). The ALCAM mutant lacking do-
mains V1V2C1 did not localize at the cell surface; therefore, this
mutant was not included in the subsequent aggregation assay.
Deletion of domain V1 reduced the aggregation capacity to the
background levels observed in the control 530 cells transfected
with empty vector (Fig. 3B). In addition, the cell lines express-
ing truncated ALCAM did not aggregate with cells expressing
wild-type ALCAM (not shown). From these findings, we con-
clude that domain V1 is essential in mediating homophilic
ALCAM interactions.
Binding of soluble ALCAM-Fc by ALCAM-expressing cells is
a sensitive assay to assess the ALCAM ligand binding capacity,
i.e. the affinity. The ligand binding capacity of the amino-
terminally truncated ALCAM molecules was compared with
that of wild-type ALCAM. In line with the results of the cell
aggregation assays, this assay also revealed that deletion of the
amino-terminal domain V1 from the cell surface-expressed
ALCAM (530/V2C1C2C3) completely abolished binding of solu-
ble ALCAM-Fc as compared with 530 melanoma cells ectopi-
cally expressing wild-type ALCAM (530/V1V2C1C2C3) (Fig. 3C).
Moreover, 530 cells expressing amino-terminally truncated
ALCAM did not adhere to immobilized ALCAM-Fc at all, while
530 cells expressing wild-type ALCAM were readily activated
to adhere to ALCAM-Fc by the addition of mAb J4-81 (Fig. 3D).
Furthermore, the function-blocking mAb AZN-L50 (10 mg/ml),
which maps to the membrane-proximal domains C2C3, did not
affect soluble ligand binding affinity by K-ALCAM cells (Fig. 4),
whereas it completely inhibited aggregation of these cells in
suspension (Fig. 2A) at the same concentration. Although the
half-maximum ligand-binding value moderately increased
from 1.5 to 3.5 mg/ml in the presence of AZN-L50, this slight
decrease in ligand binding cannot account for the complete
AZN-L50-induced inhibition of cellular aggregation of K-
ALCAM cells in suspension. In conclusion, the membrane-
distal domain V1 is critically involved in ligand binding and in
mediating stable ALCAM mediated cell-cell adhesion.
Involvement of the Membrane-proximal Domains C2C3 of
ALCAM in Homophilic Cell-Cell Interactions—In addition to
the involvement of domain V1 in ALCAM-mediated aggrega-
tion and adhesion, the specific inhibition of homophilic ALCAM
interactions by mAb AZN-L50 suggests that the membrane-
proximal domains C2C3 might be equally important in the
formation of stable cell-cell interactions. Previously, it was
TABLE I
Immunofluorescence-based epitope mapping of two monoclonal
anti-ALCAM antibodies
NH2-terminally truncated ALCAM mutants were ectopically ex-
pressed in the ALCAM-negative cell line 530. Immunofluorescence was
performed employing the mAb AZN-L50 (4 mg/ml) and J4–81 (4 mg/ml)
on methanol/acetone-fixed cells grown on glass coverslips. The epitopes
for AZN-L50 and J4–81 reside in the C2C3 Ig domains and V1 Ig
domain, respectively. Full-length ALCAM (V1V2C1C2C3) and the trun-
cated mutants V2C1C2C3 and C1C2C3 were membranously expressed,
whereas expression of the truncated mutant C2C3 was restricted to the
cytoplasm.
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shown that increased clustering of ALCAM molecules at the
cell membrane enhanced avidity, which was required for stable
ALCAM-mediated adhesion (21). To explore the effects of
partly deleting the ligand binding domain in these ALCAM
complexes on ALCAM-mediated cell aggregation, amino-termi-
nally truncated ALCAM (C1C2C3 5 DN-ALCAM) was intro-
duced into BLM melanoma cells expressing wild-type ALCAM
by stable transfection. Three independently isolated trans-
fected cell clones (BLM/DN-ALCAM-1, BLM/DN-ALCAM-2,
and BLM/DN-ALCAM-3) with different DN-ALCAM expression
levels were selected for further analysis. Overexpression of
DN-ALCAM led to a decreased aggregation capacity of the BLM
cells in a dose-dependent manner (Fig. 5, A and B), despite
unaltered expression levels of wild-type ALCAM molecules
(Fig. 5A). Therefore, elimination of domains V1V2 of ALCAM
generates a dominant negative ALCAM molecule with respect
to ALCAM-mediated homophilic cell aggregation when intro-
duced in cells expressing wild-type ALCAM. To analyze
whether the introduction of DN-ALCAM influenced the ligand
binding affinity of wild-type ALCAM, the soluble ligand bind-
ing capacity of wild-type ALCAM-expressing BLM cells co-
expressing DN-ALCAM was compared with parental BLM
cells. The BLM cell lines expressing DN-ALCAM did not show
a reduction in their capacity to bind soluble ALCAM-Fc com-
FIG. 3. The amino-terminal V-type Ig domain (V1) is essential for ligand binding and ALCAM-mediated cell aggregation. A, cell
surface expression levels of wild-type ALCAM and truncated ALCAM mutants in the ALCAM-negative human melanoma cell line 530 were
determined by flow cytometry employing the mAb AZN-L50 (4 mg/ml), which recognizes all mutants, since its epitope resides in the membrane-
proximal domains C2C3. Open histograms represent the isotype control staining, and the gray histograms represent the AZN-L50 staining of wild
type and truncated ALCAM. The constructs lacking the first or both V-type Ig domains, V1C1C2C3 or C1C2C3 respectively, were expressed at the
cell surface. The construct C2C3 lacking both V-type Ig domains and the first C-type Ig domain did not localize to the cell surface. B, cell lines
expressing wild-type or mutant ALCAM were subjected to an aggregation assay and quantified by flow cytometry. Wild-type or NH2-terminally
truncated ALCAM molecules were expressed in the ALCAM-negative melanoma cell line 530. Cells expressing wild type ALCAM aggregated
strongly, while truncation of the first amino-terminal domain V1 already completely abrogated cell aggregation. Subsequent deletion of more
domains did not have an additional effect on inhibition of adhesion. C, cells (530/V1V2C1C2C3, 530/truncated ALCAM) were incubated with soluble
ALCAM-Fc at 37 °C, and bound ALCAM-Fc was detected with a FITC-conjugated anti-human-Fc antibody. The percentage of cells that had bound
ligand was determined by flow cytometry. The ectopically ALCAM-expressing cell line 530/V1V2C1C2C3 could efficiently bind soluble ALCAM-Fc
in a concentration-dependent manner. In contrast, ALCAM-negative 530 vector control cells (530) and 530 cells expressing truncated ALCAM
(530/V2C1C2C3 and 530/C1C2C3) did not bind soluble ALCAM-Fc. D, 530 cells, or 530 cells expressing wild-type or truncated ALCAM mutants were
allowed to adhere to immobilized recombinant human ALCAM-Fc, in the presence or absence of the ALCAM mAb J4-81 (5 mg/ml) or AZN-L50 (10
mg/ml), and the percentage of adhering cells was determined. Wild-type ALCAM-expressing 530 cells were readily activated to adhere to
ALCAM-Fc by the addition of mAb J4-81, and J4-81-induced adhesion was inhibited by the addition of AZN-L50. ALCAM mutants lacking the
membrane-distal domain V1 or control-transfected 530 control cells did not adhere to immobilized ALCAM-Fc, and adhesion could not be induced
by the addition of J4-81.
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pared with the control BLM cells transfected with the empty
expression vector (BLM) (Fig. 5C). Control cells (BLM) and
cells transfected with truncated ALCAM (BLM/DN-ALCAM)
displayed similar apparent half-maximal ligand-binding val-
ues (1.6 and 1.3 mg/ml, respectively). This strongly indicates
that the decreased aggregation capacity of the DN-ALCAM-
expressing cells is due to a decrease in wild-type ALCAM
avidity rather than a decrease in the ligand binding capacity.
DISCUSSION
Heterophilic interactions between ALCAM and CD6 have
been extensively studied and mapped (18, 26). In contrast, the
molecular basis for homophilic ALCAM-ALCAM interactions
has remained largely elusive. Functional homophilic ALCAM-
mediated adhesion was demonstrated for melanoma cells (19)
and hematopoietic cells (8). Recently, we have shown that
ALCAM-mediated homophilic adhesion is dynamically regu-
lated through the actin cytoskeleton (21). However, the involve-
ment of specific domains in ALCAM-ALCAM-mediated adhe-
sion had not been addressed yet.
Here we have shown that wild-type ALCAM (V1V2C1C2C3) is
bimodular, consisting of a distinct ligand binding module com-
prising the membrane-distal domain V1 and an oligomerization
module comprising the membrane-proximal C-type domains
C2C3. Both modules are required for stable cell adhesion and
aggregation. We propose a molecular model that accounts for
the observed properties of homophilic ALCAM interactions
(Fig. 6).
Using a series of progressively amino-terminally truncated
ALCAM mutants, we found that the amino-terminal domain V1
is critically involved in the homophilic interaction. Deletion of
domain V1 not only disrupted the homophilic ALCAM-medi-
ated cell-cell interaction but also completely prevented binding
of soluble wild-type ALCAM-Fc. These observations indicated
that a direct and exclusive interaction between two opposing
domains V1 is crucial for homophilic ALCAM-mediated adhe-
sion. If multiple Ig domains were directly involved in the ho-
mophilic ALCAM interaction, cells expressing an ALCAM con-
struct that solely lacks domain V1 would be expected to display
FIG. 5. DN-ALCAM (C1C2C3), expressed in the wild-type
ALCAM-expressing cell line BLM, reduced cell aggregation in a
dose-dependent fashion without affecting soluble ligand bind-
ing affinity. Cell clones overexpressing amino-terminally truncated
ALCAM (DN-ALCAM) were generated from the parental cell line BLM
with endogenous ALCAM expression by stable transfection. Three in-
dependently isolated cell clones (BLM/DN-ALCAM-1, -2, and-3) ex-
pressing different levels of DN-ALCAM were selected for further anal-
ysis. A, expression levels of the truncated molecule were determined by
Western blotting using mAb AZN-L50 (3 mg/ml) that recognizes the
membrane-proximal Ig domains C2C3. The three established cell lines
showed different expression levels of the truncated ALCAM molecule,
while expression of the wild-type ALCAM molecule remained unal-
tered. B, the established cell lines expressing truncated ALCAM (BLM/
DN-ALCAM -1, -2, and -3) were subjected to an in vitro aggregation
assay and analyzed by two-color flow cytometry. Expression of trun-
cated ALCAM reduced the aggregation capacity of these cells as com-
pared with the vector control cell line (BLM/CTRL) in a dose-dependent
manner, and thus truncated ALCAM (C1C2C3) functions as a dominant
negative molecule with respect to wild-type ALCAM mediated aggre-
gation. C, cells (BLM, BLM/DN-ALCAM-1, -2, and -3) were incubated
with soluble ALCAM-Fc. The percentage of cells that have bound
ALCAM-Fc was determined by flow cytometry using a FITC-conjugated
anti-human Fc antibody. Ectopic DN-ALCAM expression in BLM cells
with wild-type ALCAM did not affect the capacity to bind soluble
ALCAM-Fc ligand, demonstrating that ectopic expression of DN-
ALCAM does not change the affinity of endogenously expressed AL-
CAM for soluble ALCAM-Fc.
FIG. 4. Aggregation blocking mAb AZN-L50 slightly reduced
the soluble ALCAM-Fc ligand-binding capacity of K562-ALCAM
cells. Cells (K562-ALCAM) were incubated with soluble ALCAM-Fc in
the presence or absence of the aggregation-blocking mAb AZN-L50 (10
mg/ml). The percentage of cells that have bound ALCAM-Fc was deter-
mined by flow cytometry using a FITC-conjugated anti-human-Fc an-
tibody. mAb AZN-L50 moderately increased the half-maximum ligand-
binding capacity from 1.5 to 3.5 mg/ml, indicative of a marginally
reduced ligand binding capacity.
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a residual capacity to aggregate with cells expressing wild-type
ALCAM. Moreover, truncated ALCAM-expressing cells would
be expected to bind soluble wild-type ALCAM, albeit at lower
affinity, if additional domains were involved in ligand binding.
However, both cell-cell aggregation and soluble ligand binding
were completely abolished upon deletion of the amino-terminal
domain V1. Furthermore, mAb AZN-L50, which maps to the
membrane-proximal domains C2C3, only slightly decreased the
soluble ligand binding affinity, whereas it completely inhibited
aggregation of these cells in suspension at the same concentra-
tion (10 mg/ml). It is therefore unlikely that the slight decrease
in soluble ligand binding (i.e. increase in half-maximal ligand-
binding value from 1.5 to 3.5 mg/ml in the presence of AZN-L50)
accounted for the total inhibition of ALCAM-mediated cellular
aggregation via AZN-L50. Thus, these data indicate that ligand
binding in itself is independent of the C-type Ig domains and
that homophilic ALCAM-ALCAM trans-interactions are exclu-
sively mediated by binding of opposing amino-terminal V1
domains.
mAb J4-81, which specifically recognizes domain V1, en-
hanced homophilic ALCAM-mediated cell adhesion and aggre-
gation, possibly by inducing a conformational change that pro-
motes ligand binding. KG1 cells with abundant ALCAM cell
surface expression were only able to form homotypic cell clus-
ters after activation by mAb J4-81. In contrast, spontaneous
cell clustering of K562 cells with ectopic ALCAM expression
could not be further enhanced by J4-81 treatment. These find-
ings suggest differential activation of ALCAM in these two cell
lines. We could exclude the possibility that mAb J4-81-en-
hanced aggregation and adhesion to immobilized ALCAM-Fc is
caused by cross-linking ALCAM molecules of opposing cells,
because the stimulatory effect of mAb J4-81 was temperature-
dependent and efficiently inhibited by the blocking anti-
ALCAM mAb AZN-L50. The observed enhancement of ho-
mophilic ALCAM-mediated adhesion and aggregation by mAb
J4-81 is in contrast with the inhibitory effect of this antibody on
the heterophilic ALCAM-CD6 interaction (25). This indicates
that different mechanisms are regulating the homophilic and
heterophilic ALCAM ligand binding interactions.
The inhibitory effect of AZN-L50, which is mapped to the
membrane-proximal domains C2C3, indicated that these do-
mains are also essential for the homophilic ALCAM-mediated
interaction. In analogy with other Ig superfamily molecules
like IgG, major histocompatibility complex class II, NCAM (27),
and Ng-CAM/L1-CAM (23), these C-type Ig domains are prob-
ably involved in the formation of cis-homo-oligomers at the cell
surface via lateral oligomerization. Aruffo and co-workers (28)
have speculated that ALCAM oligomerization might be essen-
tial for the heterophilic ALCAM-CD6 interaction. Recently, we
have shown that homophilic ALCAM-mediated cell adhesion is
regulated through actin cytoskeleton-dependent clustering of
ALCAM molecules at the cell surface. The resulting increased
avidity of ALCAM clusters is essential to obtain stable adhe-
sive interactions (21). Here we show that expression of DN-
ALCAM, which lacks the ligand binding domain, in the wild-
type ALCAM-expressing BLM cells reduced cell aggregation
but not soluble ligand binding. This indicates that DN-ALCAM
expression changes wild-type ALCAM avidity rather than af-
finity, suggesting a direct interaction of DN-ALCAM with wild-
type ALCAM without disturbing soluble ligand binding. In the
model proposed in Fig. 6A, ALCAM monomers form lateral
oligomers via their membrane-proximal C-type domains,
whereas the amino-terminal domain V1 mediates the actual
ligand binding. Triggering of lateral oligomerization might be a
ligand-induced event, which possibly occurs through a confor-
mational change of ALCAM. This concept is supported by pre-
vious findings that in response to ligand binding, the linkage of
ALCAM to the actin cytoskeleton is strengthened (21), which
can stabilize oligomers at the cell surface. Similar to ligand-
induced clustering, mAb J4-81 might induce a conformational
change that triggers oligomerization.
Since the epitope for ALCAM-blocking mAb AZN-L50 is lo-
calized in domains C2C3, it is tempting to speculate that the
inhibitory effect of this mAb is a result of prohibited lateral
FIG. 6. Model for the oligomeric homophilic ALCAM-ALCAM interaction. A, the membrane-proximal C-type Ig domains are involved in
lateral oligomerization of ALCAM, which is inhibited with the anti-C2C3 mAb AZN-L50, while the NH2-terminal domain V1 mediates the actual
homophilic interaction. Deletion of domain V1 resulted in a molecule that cannot bind soluble ALCAM and, therefore, has lost the ability to mediate
cell aggregation. For reasons of simplicity, the formation of a dimer is shown, but the actual mechanism could involve the formation of higher
oligomers of multiple ALCAM molecules, creating a two-dimensional lattice. B, a model for the dominant negative effect of truncated ALCAM.
Overexpression of C1C2C3 ALCAM in cells already expressing wild type ALCAM results in the formation of hetero-oligomers of wild-type and
truncated ALCAM molecules and subsequently interferes in the tight ALCAM network formation because only isolated ligand binding domains V1
are exposed instead of oligomers. Expression of the truncated molecule will reduce but not completely inhibit the ALCAM-mediated aggregation
via the Ig domain V1, because ligand-binding modules are still provided by the endogenously expressed wild-type ALCAM.
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oligomerization of ALCAM molecules by steric hindrance. This
notion is supported by the observation that mAb AZN-L50 does
not affect soluble ligand binding (Fig. 4) and therefore only
modulates ALCAM avidity. Although inhibition of cell aggre-
gation via DN-ALCAM was dependent on its expression level,
aggregation could not completely be reduced to background
levels. This residual cell-cell aggregation capacity is consistent
with the proposed model because some homophilic ALCAM-
mediated cell-cell interactions are maintained (Fig. 6B).
In conclusion, we have demonstrated that ALCAM-mediated
homophilic interactions most likely require lateral homo-oli-
gomerization through the membrane-proximal C-type Ig do-
mains, while the membrane-distal Ig domain V1 is exclusively
involved in ligand binding. Coordinate oligomerization and li-
gand binding leads to the formation of a tight, bilayered
ALCAM network, enabling stable adhesive interactions.
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